Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PTC Therapeutics Inc (NASDAQ:PTCT)

11.73
Delayed Data
As of 3:59pm ET
 -0.15 / -1.26%
Today’s Change
5.27
Today|||52-Week Range
35.76
-63.80%
Year-to-Date
Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday
Sep 20 / MotleyFool.com - Paid Partner Content
Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
Sep 20 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again
Sep 20 / MotleyFool.com - Paid Partner Content
Why PTC Therapeutics Shares Skyrocketed 20.6% Today
Sep 19 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close11.88
Today’s open11.90
Day’s range11.27 - 12.14
Volume930,564
Average volume (3 months)1,210,057
Market cap$406.9M
Dividend yield--
Data as of 3:59pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)-70.71%
Earnings growth (this year)+4.22%
Earnings growth (next 5 years)--
Revenue growth (last year)+45.64%
P/E ratioNM
Price/Sales29.63
Price/Book1.78

Competitors

 Today’s
change
Today’s
% change
MYOKMyoKardia Inc+0.90+5.95%
TLGTTeligent Inc-0.05-0.66%
VSARVersartis Inc-1.10-8.25%
DVAXDynavax Technologies...+0.23+2.11%
Data as of 3:59pm ET, 09/28/2016

Financials

Next reporting dateNovember 3, 2016
EPS forecast (this quarter)-$1.22
Annual revenue (last year)$36.8M
Annual profit (last year)-$170.4M
Net profit margin-463.60%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Class I Director
Stuart W. Peltz
Executive VP-Research, Operations &
Technology
Neil Gregory Almstead
Corporate headquarters
South Plainfield, New Jersey

Forecasts

Search for Jobs